VCEL (Vericel) Price-to-Funds-From-Operations: (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VCEL Vericel Corp VCEL
83 GF Score
Price $42.44
GF Value $54.01
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Vericel Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

VCEL
83GF Score
Vericel Corp VCEL
Price-to-Funds-From-Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vericel (VCEL) Overvalued in 2026?

Based on GuruFocus' analysis, Vericel stock appears to be undervalued. The current stock price of $42.44 is trading 21.4% below its estimated GF Value™ of $54.01. GuruFocus considers Vericel to be Modestly Undervalued.

Key valuation signals for VCEL:

  • Price-to-Funds-From-Operations:
  • GF Value™: $54.01 vs. price of $42.44 (21.4% below fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vericel Business Description

Other Exchanges ATQP:Germany
Address 64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
83GF Score

Get the complete analysis for VCEL

Price-to-Funds-From-Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.44
Price
$54.01
GF Value